Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?

31 Mar 20264 min read0 viewsJournal Feed

GIST

Journal of Clinical Oncology, Ahead of Print.

Clinical Editorial

Summary

Journal of Clinical Oncology (JCO) published a clinical update in Oncology on 31 Mar 2026. The item focuses on Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?. Open the detail page to review the full original feed content.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

ClinicalTrialsRelated by Drugpembrolizumab

Surgical Pembro +/- Olaparib w TMZ for rGBM

Oncology • 04 Mar 2026

Nat Rev OncRelated by Drugpembrolizumab

Did ATOMIC Really Improve on the Standard of Care for Mismatch Repair-Deficient Colon Cancer?

Oncology • 23 Apr 2026

Nat Rev OncRelated by Drugpembrolizumab

Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?

Oncology • 23 Apr 2026

Br J CancerRelated by Drugpembrolizumab

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

Br J CancerRelated by Drugpembrolizumab

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Oncology • 18 Apr 2026

JCORelated by Drugpembrolizumab

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Oncology • 14 Apr 2026

Feed Metadata

Source

Journal of Clinical Oncology (JCO)

Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?

GIST

Clinical Editorial

Summary

Source Reference

Related by Condition/Drug

Surgical Pembro +/- Olaparib w TMZ for rGBM

Did ATOMIC Really Improve on the Standard of Care for Mismatch Repair-Deficient Colon Cancer?

Did ATOMIC really improve on the standard of care for mismatch&#xa0;repair-deficient colon cancer?

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

PD-L1 CPS in gastroesophageal cancer: differences in routine care versus Checkmate 649 and implications for biopsy-site choice and assay standardisation

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP

Did ATOMIC really improve on the standard of care for mismatch repair-deficient colon cancer?